Welcome to our dedicated page for Biovie SEC filings (Ticker: BIVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioVie, Inc. filings document a Nevada clinical-stage biopharmaceutical company with Nasdaq-listed Class A common stock and, in certain filings, warrants tied to its capital structure. Material-event reports cover securities offerings, underwriting agreements and issuances involving units, pre-funded units and warrants.
Proxy statements and related 8-K filings describe annual meeting voting matters, director elections, board appointments and amendments to the company’s omnibus equity incentive plan. Registration statement amendments provide formal disclosure for offering activity and financial-statement periods associated with BioVie’s development-stage operations.
BioVie Inc. director James Paul Lang reported new stock option awards. On January 5, 2026, he received two grants of stock options to buy BioVie common stock at an exercise price of $1.31 per share, one covering 90,000 shares and another covering 330,500 shares, both expiring on January 5, 2031.
The 90,000-share option vests in four equal installments on February 10, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of BioVie’s 2026 annual shareholders’ meeting. For the 330,500-share option, 75% vested on January 5, 2026, with the remaining portion vesting in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. Both awards are held directly by the director and were reported as acquisitions of derivative securities.
BioVie Inc. (BIVI) has filed a Form S-8 registration statement for its 2019 Omnibus Equity Incentive Plan, which has been amended and restated through November 10, 2025. This filing allows the company to register shares that may be issued to employees, directors and other service providers as equity-based compensation under the updated plan. The document also outlines Nevada law provisions that protect and indemnify directors and officers, and notes that BioVie may advance expenses and purchase insurance for them. The filing is signed by Chief Executive Officer Cuong Do and other senior leaders, confirming their authorization to submit amendments and related documents as needed.
BioVie Inc. reported that stockholders approved an amendment and restatement of its 2019 Omnibus Equity Incentive Plan, effective November 10, 2025. The revised plan increases the number of shares of common stock authorized for issuance under the plan to 3,100,000 shares.
The plan is intended to help attract, retain, and incentivize employees, directors, and consultants, and to align their interests with stockholders. The full amended plan is incorporated by reference from the company’s September 25, 2025 definitive proxy statement.
BioVie Inc. reported results from its 2025 annual meeting of stockholders. On the September 22, 2025 record date, 7,535,080 shares were outstanding, and 3,417,857 shares were present for quorum. Stockholders elected all six director nominees to one‑year terms; each nominee received over 1.51 million "For" votes, with 1,864,509 broker non‑votes recorded on each director item.
Stockholders ratified EisnerAmper LLP as independent auditor for the fiscal year ending June 30, 2026 with 3,245,049 For, 141,868 Against, and 30,940 Abstain. They also approved an amendment and restatement of the 2019 Omnibus Equity Incentive Plan to increase the number of shares authorized for issuance to 3,100,000 (votes: 1,340,062 For, 207,794 Against, 5,492 Abstain, and 1,864,509 broker non‑votes).
BioVie Inc. filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $5.1 million, driven by operating expenses of $5.3 million (R&D $2.9 million; G&A $2.3 million). Other income, net, was $0.2 million mainly from interest income.
Cash and cash equivalents rose to $25.0 million from $17.5 million at June 30, 2025, supported by net proceeds of approximately $10.5 million from an August 2025 underwritten offering of units and pre-funded units, each including warrants exercisable at $2.50. Net cash used in operations was $3.0 million.
The company advanced its clinical programs: a Phase 2b study in Parkinson’s disease commenced in April 2025, and the DOD-funded Long COVID Phase 2 study continued, with $336,000 in grant reimbursements recognized this quarter. BioVie disclosed “substantial doubt” about its ability to continue as a going concern, noting dependence on additional financing. A 1-for-10 reverse stock split became effective July 7, 2025. Shares outstanding were 7,540,316 as of November 7, 2025.
BioVie Inc. (BIVI) filed a Form 3, the initial statement of beneficial ownership for a board member. The reporting person is a Director, and the filing states that no securities are beneficially owned as of the event date 07/17/2025. The form indicates it was filed by one reporting person. This is a routine ownership disclosure that establishes the insider’s baseline holdings at the time of becoming subject to reporting.
BioVie Inc. (BIVI) disclosed a Form 3 filed by a director, indicating no securities are beneficially owned by the reporting person. The filing identifies the relationship as Director and notes the event date as 07/17/2025. The form was filed by one reporting person.
BioVie Inc. filed a post-effective amendment to its Form S-1 registration statement, acting as an exhibits-only update. The amendment’s sole purpose is to add the consent of EisnerAmper LLP as the company’s independent registered public accounting firm, covering its report dated August 15, 2025 on BioVie’s financial statements for the year ended June 30, 2025. The consent is filed as Exhibit 23.1, and the rest of the prospectus and Part II of the registration statement remain unchanged.
BioVie Inc. solicits shareholder votes at its virtual annual meeting and presents director nominees, auditor ratification and an amendment to increase shares available under its 2019 equity plan to 3,100,000 shares. The proxy names the board slate including Cuong Do (President & CEO) and committee chairs for audit, compensation and governance. Compensation tables show named executive officer pay components: for example, the CEO's total compensation entries include cash and equity components (reported totals such as $777,082 for one year and $420,621 for another row). Director and NEO equity holdings and outstanding option/RSU schedules are disclosed, including a listed beneficial ownership aggregate of 65,312 shares (0.9%) for listed insiders. Audit fees paid to the auditor are disclosed (audit-related fees shown as $99,750 and tax fees $26,250).